Phase II trial of fazarabine (arabinofuranosyl-5-azacytidine) in patients with advanced pancreatic adenocarcinoma. Academic Article uri icon

Overview

abstract

  • We conducted a phase II evaluation of fazarabine 1.75-2.0 mg/m2/hr over 72 hours every 28 days in 14 previously untreated patients with advanced adenocarcinoma of the pancreas. The initial dose was 1.75 mg/m2/hr in 10 patients, and 2.0 mg/m2/hr in 4 patients. The dose was escalated in 8 patients, including all 4 who started at the higher dose level. Toxicity was unexpectedly mild. The median WBC nadir was 4.4 (range: 2.4-15.8) x 10(3)/microliters, the median absolute neutrophil nadir was 3.2 (range: 0.9-13.0) x 10(3)/microliters, and the median platelet count was 134.0 (range: 48.0-291.0) x 10(3)/microliters. Gastrointestinal toxicity was generally mild. No major responses were seen, excluding, with 95% confidence, a response rate in excess of 20%.

publication date

  • August 1, 1992

Research

keywords

  • Adenocarcinoma
  • Antineoplastic Agents
  • Azacitidine
  • Pancreatic Neoplasms

Identity

Scopus Document Identifier

  • 0026452576

Digital Object Identifier (DOI)

  • 10.1007/BF00877247

PubMed ID

  • 1385354

Additional Document Info

volume

  • 10

issue

  • 3